by Raynovich Rod | Nov 21, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
NanoString Technologies (NSTG $12) is an early stage, life science research Company with a proprietary platform product, the nCounter (R) Analysis System. The nCounter utilizes a proprietary bar code chemistry and technology that can multiplex hundreds of gene...
by Raynovich Rod | Nov 21, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
Another Strong Day in Life Science Stocks Carl Icahn, activist investor takes a 13% stake in Hologic. Hologic (HOLX $22.82) was added to our portfolio on 4/9/13 but has been a laggard due to earnings misses. The stock is up 2.4% on a volume of 25M shares. Many stocks...
by Raynovich Rod | Nov 14, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
Rayno Diagnostics and Tools Focus Stocks: 2013 Performance YTD A diversified life science portfolio must include clinical diagnostics and tools stocks because the synergies between therapy and diagnostics have never been stronger. Breakthroughs in molecular...
by Raynovich Rod | Sep 25, 2013 | Clinical Diagnostics and Tools
Foundation Medicine (FMI) Soars on IPO-Up 75% Foundation Medicine (FMI $32.30), based in Cambridge MA, went public today at $18 offering 5,888,888 M shares and promptly went up 79% on volume over 4.5M shares as of early trading. See IPO Desktop for more information...
by Raynovich Rod | Aug 26, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Life science stocks resumed their upward trajectory today with major ETFs (FBT,IBB,XBI) up over 2% and a green screen for the sector. Mid-cap biopharma stocks are strong once again. The IBB hit an August low of $187 on August 19 after a high in early August near $201....
by Raynovich Rod | Aug 20, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
Diagnostics Company Stocks Are Off Their 2013 Highs Life science tools and diagnostics stocks are near all time highs despite stretched valuations because of a strong secular biotech bull market and perceived synergy with biopharmaceuticals. Key themes are point of...
by Raynovich Rod | Aug 13, 2013 | Biopharmaceuticals
Market Can’t Stay Down in Quiet Trading After a couple of lackluster trading days the market perked up as economic news continues positive with retail sales up for the fourth consecutive month and many analysts believing Europe is coming out of recession. And...
by Raynovich Rod | Jul 25, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
Diagnostics and Tools Stocks Are At New Highs We will be attending the American Association of Clinical Chemistry Meeting in Houston next week. Our focus stocks are summarized below and as you can see they have already made huge moves this year.In the past we have...
by Raynovich Rod | Jun 20, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Rayno Diagnostics and Tools Portfolio Prices as of 5/29/13 Top 2013 Winners: ABAX, ALR, CSII, GHDX, ILMN, TMO, VRML Sector high was in mid-May Less volatile than biopharma but more dependent on earnings Five companies on focus list were acquired over 3 years...
by Raynovich Rod | Jun 13, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
6/14 Supreme Court Ruling on Genetic Tests Takes Down Myriad Stock (MYGN $30.50)-Off Another 3% but still up 13% YTD. The Supreme Court ruling opens up competition for Myriad’s breast cancer tests as well as other genetic disease markers.The immediate reaction...
